ATOS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Atossa Therapeutics Inc (ATOS) is not a strong buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock lacks clear positive catalysts, has weak financial performance, and no strong trading signals. While analysts maintain a Buy rating, the lack of significant news, neutral insider and hedge fund activity, and poor growth trends suggest holding off on investment at this time.
The MACD is positive and expanding, indicating bullish momentum. RSI is at 75.268, in the neutral zone, and moving averages are converging, showing no clear trend. The stock is trading near its R1 resistance level of 5.649, with limited upside potential in the short term.
Analysts maintain a Buy rating with a price target increase from $7 to $25, citing ongoing breast cancer studies and a cash runway for at least one year.
The company paused development of Z-endoxifen in metastatic breast cancer, which may have impacted investor confidence. Financial performance remains weak with no revenue growth and significant net losses. No significant insider, hedge fund, or congress trading activity.
In Q4 2025, revenue remained at $0 with no YoY growth. Net income improved by 72.32% YoY but remains negative at -$10.94M. EPS increased by 69.33% YoY but is still negative at -1.27. Gross margin remains at 0%.
Analysts maintain a Buy rating but have mixed price target adjustments. H.C. Wainwright raised the target to $25 citing the reverse stock split, while Craig-Hallum lowered it to $10 due to paused development in metastatic breast cancer.
